Shalby Limited: Navigating Challenges, Charting Growth in Q3 FY26

Shalby Limited, a prominent player in India's healthcare sector, recently announced its financial results for the third quarter of Fiscal Year 2026 (Q3 FY26). The quarter presented a mixed bag of operational challenges and strategic advancements, particularly in its hospital and MedTech divisions. The company reported a consolidated revenue of INR 279.4 crore, a marginal year-on-year decline of 0.6% from INR 281.1 crore in Q3 FY25. Despite this slight dip in top-line, Shalby demonstrated significant improvement in its bottom-line, with consolidated Profit After Tax (PAT) turning positive at INR 1.3 crore, a notable recovery from a negative PAT of INR 3 crore in the corresponding quarter last year. Consolidated EBITDA stood at INR 37.5 crore, with a margin of 13.4%.

The hospital business, a core segment for Shalby, faced temporary headwinds during the quarter. Management highlighted that negotiations with a few major insurance companies led to a temporary halt in services for approximately 2 to 2.5 months. This directly impacted inpatient and outpatient volumes. However, the company successfully re-signed these contracts by November-end, and a positive patient flow has been observed in the subsequent period. Additionally, Shalby experienced some doctor attrition, losing two high-end specialists in different units. This was partially offset by the recruitment of 40 new doctors during the quarter, indicating a proactive approach to talent management. The company also noted an improvement in government business rates, leading to higher realization per patient, which helped to compensate for some of the revenue impact.

Strategic Investments and Operational Enhancements

Shalby continues to invest heavily in strategic initiatives aimed at enhancing clinical excellence and operational efficiency. The company has commissioned robotic surgery systems at two centers, expanding its capabilities in high-margin tertiary care specialties like Urology, Oncology, Gynecology, and complex abdominal surgeries. Furthermore, new PET-CT scanners and radiotherapy machines have been installed across three units, significantly bolstering cancer care capacity. Orthopedic surgical robots are now operational at the Delhi and Ahmedabad units, contributing to improved precision outcomes and a premium procedure mix. These technology investments are expected to drive higher ARPOB (Average Revenue Per Occupied Bed) and improve EBITDA margins in the coming quarters.

In terms of advanced care, Shalby successfully rolled out Kidney, Liver Transplant programs, and Bone Marrow Transplant (BMT) services. In Q3 FY26 alone, 32 transplants (29 Kidney, 3 Liver) were performed, contributing to a total of over 525 transplants across various Shalby units. This focus on high-acuity services positions Shalby as a leading tertiary and quaternary care center, characterized by longer patient lengths of stay.

MedTech: A Turnaround Story

The MedTech division emerged as a significant growth driver, showcasing a remarkable turnaround in profitability. Consolidated MedTech revenue grew by 29% year-on-year to INR 30.38 crore in Q3 FY26, compared to INR 23.49 crore in Q3 FY25. More impressively, the segment's consolidated EBITDA turned positive at INR 0.7 crore, a substantial improvement from a loss of INR 6.9 crore in the prior year's corresponding quarter. This positive shift is attributed to operating leverage, rigorous cost optimization, and an enhanced product mix.

Management emphasized that the capacity issues, which previously hindered the MedTech segment's growth, are now 80-85% resolved. Furthermore, the cost of goods manufactured at the implant business factory has been reduced by almost 50% compared to four and a half years ago, highlighting significant manufacturing efficiencies. The company has also been aggressive in new product development, launching 5 to 6 new products across various geographies in the last 12 months. The global expansion roadmap for MedTech is robust, with regulatory approvals secured in Malaysia and Argentina, and dossiers submitted in South Korea, Vietnam, and Iran, alongside active discussions in several other countries like Ethiopia, Paraguay, Sri Lanka, and Russia. This structured expansion is expected to drive accelerated international growth over the next 12 to 14 months.

Outlook and Strategic Focus

Shalby's management expressed confidence in the company's future trajectory. They anticipate double-digit volume growth in the hospital business and a 5-6% ARPOB growth in the coming year. The net debt is expected to reduce over the next 12 months, with no significant capex planned for the hospital or implant businesses during this period. The MedTech segment is projected to continue its strong growth at 40-60% year-on-year. The company's focus remains on leveraging its existing bed capacity, which allows for substantial growth without major new investments. The Delhi unit, in particular, is targeted to achieve an average occupancy of 40 beds for FY27, which would significantly improve its performance.

Shalby's Q3 FY26 results underscore a period of strategic recalibration and focused execution. Despite some operational challenges, the company's proactive measures in talent acquisition, technology adoption, and payer mix optimization, coupled with the strong turnaround in its MedTech division, position it for sustained growth and improved profitability in the quarters ahead. The emphasis on clinical excellence and a disciplined capital allocation strategy reinforces investor confidence in Shalby's long-term vision.